RxDoctor Payments Data

David Kovacs, MD

Internal Medicine · Mission Viejo, CANPI 1861633083

Payments from drug & device makers

$24,987in general payments, 2019–2025

Across 1,151 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$5K
  • AbbVie$5K
  • Johnson & Johnson$2K
  • Novartis$2K
  • UCB, Inc.$2K
  • Lilly USA, LLC$2K
  • plus $8K from 35 others

What the payments were for

  • Consulting fees$5602%
  • Travel & lodging$500%
  • Food & beverage$24,03396%
  • Education$3441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,987 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$152,699
Medicare patients
418
Services billed
4,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab69$468,047
Enbrel SureclickEtanercept42$329,602
RemicadeInfliximab27$155,189
Simponi AriaGolimumab16$140,767
Xeljanz XrTofacitinib Citrate24$133,192
Teriparatide11$42,257
Hydroxychloroquine Sulfate512$21,989
Celecoxib181$10,822
MethotrexateMethotrexate Sodium346$10,396
Colchicine112$10,028
Leflunomide88$6,330
Prednisone469$3,869
Mycophenolate Mofetil14$2,800
Allopurinol206$1,593
Gabapentin106$1,493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonRemicade, Simponi Aria$1,969$295,95643 claims
Alvogen IncTeriparatide$95$42,25711 claims
Scilex Pharmaceuticals Inc.Colchicine$65$10,028112 claims
Fresenius Kabi USA, LLCSodium Chloride$459$4911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →